IP Library Granted Patent US 9,198,999
Granted Patent B2
US 9,198,999 · App. 13/787,327 · Granted Dec 1, 2015

Drug-eluting rotational spun coatings and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,198,999
App. No.
13/787,327
Granted
Dec 1, 2015
Kind
B2
Abstract

Drug-eluting rotational spun coatings that include one or more therapeutic agents may be used to coat a medical device. The medical devices include, for example, balloon catheters, vascular grafts and stents, which are coated with drug-eluting rotational spun materials that may be used to deliver a therapeutic agent to a target tissue or body lumen.

Claims (33)

1. A medical device comprising a drug-eluting rotational spun coating, wherein the drug-eluting rotational spun coating comprises a therapeutic agent in an amount configured to deliver a pharmaceutically effective dose to a target tissue, wherein the drug-eluting rotational spun coating is configured to provide a controlled release of the therapeutic agent to the target issue in approximately 5 minutes or less, wherein the drug-eluting rotational spun coating comprises at least two layers of rotational spun fibers having a diameter of between about 50 nanometers and about 3 micrometers, and wherein the drug-eluting rotational spun coating has a percent porosity of between about 30% and about 80%.

2. The medical device of claim 1 , wherein the therapeutic agent is selected from at least one of rapamycin, paclitaxel, a bismuth-containing compound, heparin, and analogs of any of the foregoing.

3. The medical device of claim 1 , wherein the rotational spun coating is configured to deliver a dose of a therapeutic agent to a target tissue of between about 100 μg and about 600 μg.

4. The medical device of claim 1 , wherein the drug-eluting rotational spun coating comprises at least one of nylon 6-6, polyethylene, polypropylene, PTFE, and Kevlar.

5. The medical device of claim 1 , wherein the drug-eluting rotational spun coating comprises at least one of fibrin, fibrinogen, chitin, chitosan, starch, collagen, hyaluronic acid, alginate, dextran, cellulose, and mixtures thereof.

6. The medical device of claim 1 , wherein the drug-eluting rotational spun coating comprises rotational spun fibers between 750 nanometers and 2 microns in diameter.

7. The medical device of claim 1 , wherein the drug-eluting rotational spun coating comprises a percent porosity of between about 40% and about 60%.

8. The medical device of claim 1 , wherein the drug-eluting rotational spun coating comprises at least one layer of a drug-eluting rotational spun material, and at least one layer of a non-drug-eluting rotational spun material.

9. The medical device of claim 1 , further comprising at least one layer of a non-spun material.

10. The medical device of claim 1 , wherein the therapeutic agent is associated with the drug-eluting rotational spun coating via covalent or ionic bonding.

11. The medical device of claim 1 , further comprising an electrospun coating.

12. The medical device of claim 1 , wherein the medical device is selected from at least one of a balloon, a stent, a catheter or a vascular graft.

13. A medical device comprising a drug-eluting rotational spun coating and at least one layer of non-spun material, wherein the drug-eluting rotational spun coating comprises a therapeutic agent in an amount configured to deliver a pharmaceutically effective dose to a target tissue, wherein the drug-eluting rotational spun coating comprises at least two layers of rotational spun fibers having a diameter of between about 50 nanometers and about 3 micrometers, and wherein the drug-eluting rotational spun coating has a percent porosity of between about 30% and about 80%.

14. The medical device of claim 13 , wherein the therapeutic agent is selected from at least one of rapamycin, paclitaxel, a bismuth-containing compound, heparin, and analogs of any of the foregoing.

15. The medical device of claim 13 , wherein the rotational spun coating is configured to deliver a dose of a therapeutic agent to a target tissue of between about 100 μg and about 600 μg.

16. The medical device of claim 13 , wherein the drug-eluting rotational spun coating is configured to provide a controlled release of a therapeutic agent to a target tissue.

17. The medical device of claim 13 , wherein the drug-eluting rotational spun coating comprises at least one of nylon 6-6, polyethylene, polypropylene, PTFE, and Kevlar.

18. The medical device of claim 13 , wherein the drug-eluting rotational spun coating comprises at least one of fibrin, fibrinogen, chitin, chitosan, starch, collagen, hyaluronic acid, alginate, dextran, cellulose, and mixtures thereof.

19. The medical device of claim 13 , wherein the drug-eluting rotational spun coating comprises rotational spun fibers between 750 nanometers and 2 microns in diameter.

20. The medical device of claim 13 , wherein the drug-eluting rotational spun coating comprises a percent porosity of between about 40% and about 60%.

21. The medical device of claim 13 , wherein the drug-eluting rotational spun coating comprises at least one layer of a drug-eluting rotational spun material, and at least one layer of a non-drug-eluting rotational spun material.

22. The medical device of claim 13 , further comprising an electrospun coating.

23. The medical device of claim 13 , wherein the medical device is selected from at least one of a balloon, a stent, a catheter or a vascular graft.

24. A medical device comprising a drug-eluting rotational spun coating, wherein the drug-eluting rotational spun coating comprises a therapeutic agent in an amount configured to deliver a pharmaceutically effective dose to a target tissue, wherein the therapeutic agent is associated with the drug-eluting rotational spun coating via covalent or ionic bonding, wherein the drug-eluting rotational spun coating comprises at least two layers of rotational spun fibers having a diameter of between about 50 nanometers and about 3 micrometers, and wherein the drug-eluting rotational spun coating has a percent porosity of between about 30% and about 80%.

25. The medical device of claim 24 , wherein the therapeutic agent is selected from at least one of rapamycin, paclitaxel, a bismuth-containing compound, heparin, and analogs of any of the foregoing.

26. The medical device of claim 24 , wherein the rotational spun coating is configured to deliver a dose of a therapeutic agent to a target tissue of between about 100 μg and about 600 μg.

27. The medical device of claim 24 , wherein the drug-eluting rotational spun coating comprises at least one of nylon 6-6, polyethylene, polypropylene, PTFE, and Kevlar.

28. The medical device of claim 24 , wherein the drug-eluting rotational spun coating comprises at least one of fibrin, fibrinogen, chitin, chitosan, starch, collagen, hyaluronic acid, alginate, dextran, cellulose, and mixtures thereof.

29. The medical device of claim 24 , wherein the drug-eluting rotational spun coating comprises rotational spun fibers between 750 nanometers and 2 microns in diameter.

30. The medical device of claim 24 , wherein the drug-eluting rotational spun coating comprises a percent porosity of between about 40% and about 60%.

31. The medical device of claim 24 , wherein the drug-eluting rotational spun coating comprises at least one layer of a drug-eluting rotational spun material, and at least one layer of a non-drug-eluting rotational spun material.

32. The medical device of claim 24 , further comprising an electrospun coating.

33. The medical device of claim 24 , wherein the medical device is selected from at least one of a balloon, a stent, a catheter or a vascular graft.

Assignments (2)
SECURITY INTEREST Recorded Aug 8, 2016
From: MERIT MEDICAL SYSTEMS, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 039609/0918 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2013
From: HALL, JOHN WILLIAM; SIMMONS, RACHEL L.; HOPKINSON, AARON; DOLMATCH, BART; ELLER, ZEKE; KELLAR, ROBERT S.
To: MERIT MEDICAL SYSTEMS, INC.
Reel/Frame 030481/0954 →